Shield Therapeutics plc Total Liabilities

Latest as of June 2025: GBX76.96 Million GBX ≈ $9.36K USD

Shield Therapeutics plc total liabilities. Based on the latest financial reports, Shield Therapeutics plc (STX) has total liabilities worth GBX76.96 Million GBX (≈ $9.36K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check STX asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Shield Therapeutics plc (2013–2024)

Total liabilities of Shield Therapeutics plc from 2013 to 2024. This chart illustrates how Shield Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data.

Shield Therapeutics plc Competitors by Total Liabilities

The table below lists competitors of Shield Therapeutics plc ranked by their total liabilities.

Company	Country	Total Liabilities
Longevity Health Holdings, Inc. NASDAQ:XAGE	USA	$8.54 Million
Aloro Mining Corp V:AORO	Canada	CA$2.44 Million
GCL Global Holdings Ltd Warrants NASDAQ:GCLWW	USA	$123.85 Million
ROBUS GROUP AS EO -60 F:LH2	Germany	€165.85K
Fashion Bel Air S.A PA:ALFBA	France	€5.19 Million
CENTAURUS ENERGY INC. F:72M0	Germany	€5.63 Million
H&G High Conviction Ltd AU:HCF	Australia	AU$22.20K

Liability Composition Analysis (2013–2024)

This chart breaks down Shield Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Shield Therapeutics plc asset portfolio.

Liquidity & Leverage Metrics

Shield Therapeutics plc Total Liabilities Ratios Explained

Shield Therapeutics plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	0.83	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-5.18	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shield Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shield Therapeutics plc (2013–2024)

The table below shows the annual total liabilities of Shield Therapeutics plc from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	GBX46.95 Million ≈ $5.71K	+77.25%
2023-12-31	GBX26.49 Million ≈ $3.22K	+59.11%
2022-12-31	GBX16.65 Million ≈ $2.03K	+392.51%
2021-12-31	GBX3.38 Million ≈ $411.25	+50.09%
2020-12-31	GBX2.25 Million ≈ $274.00	-46.05%
2019-12-31	GBX4.17 Million ≈ $507.86	+41.44%
2018-12-31	GBX2.95 Million ≈ $359.05	-21.58%
2017-12-31	GBX3.76 Million ≈ $457.85	-5.64%
2016-12-31	GBX3.99 Million ≈ $485.22	-81.45%
2015-12-31	GBX21.50 Million ≈ $2.62K	+11.48%
2014-12-31	GBX19.29 Million ≈ $2.35K	+139.66%
2013-12-31	GBX8.05 Million ≈ $979.21	--

About Shield Therapeutics plc

LSE:STX UK Drug Manufacturers - Specialty & Generic

Market Cap

$415.82K

GBX3.42 Billion GBX

Market Cap Rank

#31127 Global

#943 in UK

Share Price

GBX3.20

Change (1 day)

-3.03%

52-Week Range

GBX3.05 - GBX12.20

All Time High

GBX185.02